NA
LKFT

Navellier & Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Navellier & Associates’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,400
Closed -$214K – 271
2015
Q4 		$214K Sell
3,400
-8,380
-71% -$428K 0.02% 201
2015
Q3 		$480K Sell
11,780
-255
-2% -$14.7K 0.05% 162
2015
Q2 		$620K Buy
+12,035
New +$639K 0.05% 172

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Navellier & Associates's LKFT Position: Q1 2016 in Review

Navellier & Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2016, closing a stake of 3,400 shares — an estimated $214K sold.

Navellier & Associates first reported a position in LKFT in Q2 2015 and held it in 3 quarters. The position peaked at $620K in Q2 2015. 32 funds tracked by Wall St. Rank hold LKFT as of Q1 2016.

  • Navellier & Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2016 after selling out during the quarter.
  • Navellier & Associates sold 3,400 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2016, an estimated $214K.
  • Navellier & Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and held it in 3 quarters.
  • Navellier & Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $620K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2016.

Based on Navellier & Associates's 13F filing for Q1 2016, filed 13 May 2016.